Lidbree

Lidocaine, the active ingredient in Lidbree, is a local anesthetic presented as a solution for intrauterine use. It provides rapid, reversible loss of sensation in the uterine lining, facilitating procedures such as hysteroscopy, intrauterine device placement, and uterine curettage in adult women.

GNH USA supplies Lidbree as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets. The company adheres to EU GMP standards and provides reliable logistics for bulk and unit‑dose shipments.

Lidbree is employed as a local anesthetic for intrauterine procedures, providing pain relief during interventions that involve the uterine cavity.

- Hysteroscopic surgery: facilitates visualization and reduces patient discomfort during diagnostic and operative hysteroscopy. - Intrauterine device (IUD) insertion: minimizes insertion pain and uterine cramping. - Uterine curettage: provides anesthesia for dilation and curettage (D&C) and related sampling procedures.

Lidbree may cause a range of adverse reactions, most of which are related to its local anesthetic properties or systemic absorption.

Common Side Effects: - Burning or stinging at the application site. - Mild uterine cramping or discomfort. - Nausea or light‑headedness. - Headache. - Transient dizziness. - Local irritation or erythema.

Serious or Rare Side Effects: - Systemic toxicity presenting as seizures or altered mental status. - Cardiac arrhythmias or hypotension. - Severe allergic reaction (anaphylaxis). - Methemoglobinemia. - Persistent numbness beyond the procedure. - Respiratory depression.

When using Lidbree, clinicians should observe several precautionary measures to minimize risk and ensure safe administration. - Allergy assessment: verify no known hypersensitivity to lidocaine or other amide‑type anesthetics. - Dose limitation: use the lowest effective volume for the specific procedure. - Cardiovascular monitoring: observe heart rate and blood pressure during and after administration. - Caution in cardiac disease: avoid or reduce use in patients with severe conduction abnormalities or heart block. - Pregnancy considerations: evaluate risk‑benefit ratio before use in pregnant women. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Lidbree can interact with other medicines, potentially altering its safety profile or efficacy.

Major Interactions (Avoid): - Concurrent use of other local anesthetics: may increase risk of systemic toxicity. - Class I antiarrhythmic agents (e.g., quinidine, procainamide): can potentiate cardiac conduction effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise lidocaine plasma levels.

Moderate Interactions (Monitor Closely): - Central nervous system depressants (e.g., benzodiazepines, opioids): may enhance sedation. - Beta‑blockers: can affect heart rate response to lidocaine. - Diuretics (e.g., furosemide): may alter plasma protein binding. - Calcium channel blockers: may influence cardiac electrophysiology.